0001654954-20-005036.txt : 20200507 0001654954-20-005036.hdr.sgml : 20200507 20200507132715 ACCESSION NUMBER: 0001654954-20-005036 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200502 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20200507 DATE AS OF CHANGE: 20200507 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PREMIER BIOMEDICAL INC CENTRAL INDEX KEY: 0001515740 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 272635666 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-54563 FILM NUMBER: 20855579 BUSINESS ADDRESS: STREET 1: P.O. BOX 25 CITY: JACKSON CENTER STATE: PA ZIP: 16133 BUSINESS PHONE: 724-633-7033 MAIL ADDRESS: STREET 1: P.O. BOX 25 CITY: JACKSON CENTER STATE: PA ZIP: 16133 8-K 1 biei_8k.htm CURRENT REPORT biei_8k
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 8-K
 
Current Report
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
 
 
Date of Report (Date of earliest event reported): May 2, 2020
 
PREMIER BIOMEDICAL, INC.
(Exact name of registrant as specified in its charter)
 
Nevada
(State or other
jurisdiction of incorporation)
 
000-54563
(Commission
File Number)
 
27-2635666
(I.R.S. Employer
Identification No.)
 
 
 
 
 
 
 
 
 
 
P.O. Box 25
Jackson Center, PA 16133
 (Address of principal executive offices) (zip code)
 
 
 
 
 
 
 
 
 
 
(814) 786-8849
(Registrant’s telephone number, including area code)
 
 
 
 
 
 
 
 
 
 
 (Former name or former address, if changed since last report.)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
[_] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
[_] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
[_] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
[_] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company  [_]
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  [_]
 


 
 
Section 5 – Corporate Governance and Management
 
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
 
On May 2, 2020, Mitchell Felder resigned as one of the members of our Board of Directors, and as the Chairman of the Board of Directors. Mr. Felder will remain as Chairman of our Scientific Advisory Board. Mr. Felder’s resignation did not involve any disagreement with the Company or other management relating to the Company’s operations, policies, practices or otherwise.
 
                                                              
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
Premier Biomedical, Inc.
 
 
 
 
Dated: May 7, 2020
/s/ William Hartman
 
By: William Hartman
 
Its: Chief Executive Officer